LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Kodu・Aktsiate loetelu・Editas Medicine Inc

Editas Medicine Inc

Suletud

SektorTervishoid

2.76 3.37

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.73

Max

2.76

Põhinäitajad
By Trading Economics
Sissetulek	-19M -25M
Müük	-22M 2.8M
Aktsiakasum	-0.26
Kasumimarginaal	-882.444
Töötajad	87
EBITDA	-19M -25M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+139.13% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-52M 241M
Eelmine avamishind	-0.61
Eelmine sulgemishind	2.76

Uudiste sentiment

By Acuity

50%

146 / 345 Pingereas Healthcare

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24. mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24. mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24. mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24. mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24. mai 2026, 22:26 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24. mai 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24. mai 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24. mai 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24. mai 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24. mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24. mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23. mai 2026, 08:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

23. mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 21:10 UTC

Tulu

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2026, 19:47 UTC

Tulu

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22. mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22. mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22. mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22. mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22. mai 2026, 18:35 UTC

Omandamised, ülevõtmised, äriostud

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22. mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22. mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

139.13% tõus

12 kuu keskmine prognoos

Keskmine 6.6 USD 139.13%

Kõrge 15 USD

Madal 4 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

146 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.